How did Bausch Health's revenue and expenses shift in Q4 2024?

Bausch Health's revenue and expenses in Q4 2024 showed a significant shift, primarily due to changes in its business segments:

1. Revenue Shift:
   • The company's total revenue decreased from $5.9 billion to $4.34 billion, indicating a decline in overall sales.
   • The most notable decrease was in the segment previously reported as $5.9 billion, which dropped to $4.34 billion.
2. Cost of Goods Sold and Gross Margin:
   • The Cost of Goods Sold (COGS) remained at $727 million, which is a fixed cost.
   • However, the Gross Margin decreased from 71.9% to 71.6%, suggesting that the company's profitability margin on sales has declined.
3. Operating Expenses and Net Income:
   • Operating Expenses increased from $230 million to $330 million, which could be a result of cost inefficiencies or strategic investments.
   • Despite the increase in operating expenses, the Net Income remained stable at $98 million.
4. Segment Performance:
   • The segment previously reported as Bausch + Lomb/International saw a significant drop in revenue, which could be a critical area of focus for the company's strategic planning.
   • The Salix segment also showed a substantial decrease in revenue, which may require attention to improve performance.

In conclusion, Bausch Health faced a challenging quarter with a significant decline in revenue and a slight increase in operating expenses. The company needs to address the revenue decline, especially in the Bausch + Lomb/International and Salix segments, to improve its overall financial performance.